Last quarter (Q3 2023), Cyclacel Pharmaceuticals's total revenue was $16.00K, an increase of Infinity% from the same quarter last year. In Q3, Cyclacel Pharmaceuticals's net income was $-6.08M. See Cyclacel Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 389.00K	-	-	$ 0.00	$ 0.00	$ 150.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 389.00K	-	-	-	-	-
Operating Expense	$ 66.95M	$ 27.66M	$ 22.94M	$ 10.64M	$ 9.68M	$ 9.70M
Operating Income	$ -28.94M	$ -27.66M	$ -22.94M	$ -10.64M	$ -9.68M	$ -9.55M
Net Non Operating Interest Income Expense	$ 365.00K	$ 210.00K	$ 16.00K	$ 42.00K	$ 224.00K	$ 331.00K
Other Income Expense	$ -55.00K	$ -1.30M	$ -144.00K	$ 913.00K	$ 332.00K	$ 592.00K
Pretax Income	$ -28.86M	$ -25.91M	$ -22.73M	$ -9.68M	$ -9.13M	$ -8.63M
Tax Provision	$ -4.16M	$ -4.72M	$ -3.85M	$ -1.24M	$ -1.30M	$ -1.34M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -24.90M	$ -21.40M	$ -19.09M	$ -12.42M	$ -8.03M	$ -7.49M
Basic EPS	$ -2.47	$ -1.90	$ -2.14	$ -3.42	$ -9.80	$ -12.40
Diluted EPS	$ -2.47	$ -1.90	$ -2.14	$ -3.42	$ -9.80	$ -12.40
Basic Average Shares	$ 48.99M	$ 11.26M	$ 8.93M	$ 3.63M	$ 816.09K	$ 604.71K
Diluted Average Shares	$ 48.99M	$ 11.26M	$ 8.93M	$ 3.63M	$ 816.09K	$ 604.71K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 66.95M	$ 27.66M	$ 22.94M	$ 10.64M	$ 9.68M	$ 9.70M
Net Income From Continuing And Discontinued Operation	$ -24.70M	$ -21.20M	$ -18.89M	$ -8.45M	$ -7.83M	$ -7.29M
Normalized Income	$ -13.99M	-	-	$ -8.46M	$ -7.92M	$ -7.21M
Interest Expense	-	-	-	-	-	-
EBIT	$ -28.98M	$ -25.91M	$ -22.73M	$ -10.64M	$ -9.68M	$ -9.55M
EBITDA	$ -28.95M	$ -25.88M	$ -22.69M	$ -10.62M	$ -9.66M	$ -9.52M

Currency in USD

Cyclacel Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing